A novel point of care test for oral and oropharyngeal cancer risk

口腔癌和口咽癌风险的新型护理点测试

基本信息

批准号：
9239502
负责人：
Joseph A Califano
金额：
$ 59.39万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-01-03 至 2021-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9239502
关键词：
Affect Aftercare Alcohol consumption Bedside Testings Biological Assay Biological Sciences CD44 gene Cancer Control Cancer Patient Case-Control Studies Clinical Data Detection Development Devices Disease Disease Outcome Disease-Free Survival Early Diagnosis Environment Frequencies Human Papillomavirus Human papilloma virus infection Incidence Laboratories Malignant Neoplasms Methodology Modeling Morbidity - disease rate Oral Oral Diagnosis Oral cavity Oropharyngeal Performance Populations at Risk Prognostic Marker Proteins Recurrence Research Design Risk Risk Assessment Risk Factors Salivary Squamous cell carcinoma Techniques Testing Tissues Tobacco use Treatment Cost Validation base cancer risk improved industry partner malignant mouth neoplasm malignant oropharynx neoplasm novel outcome forecast outcome prediction point of care prognostic assays prognostic value prospective therapy outcome tumor

项目摘要

Squamous cell carcinomas, including those of the mouth and oropharynx, comprise more than 90% of all cancers affecting these tissues (1). Simply providing universal, expert clinical examination would not meet the need for improved early diagnosis of oral/oropharyngeal cancer. Development and validation of an accurate test to assess risk of oral/oropharyngeal cancer has the potential to improve therapeutic outcomes, reduce associated morbidity, and reduce treatment costs. The combination of salivary rinse soluble CD44 (SolCD44) and salivary rinse total protein identified by Vigilant Biosciences has shown to be much more accurate in the detection of oral cancers than conventional detection techniques (5,30,31) In addition, increased SolCD44 is independently associated with poor prognosis in these cancers. This project will 1) continue the development of a unique, stable, inexpensive, noninvasive, easy to use, oral/oropharyngeal cancer specific, rapid point-of-care (POC) risk assessment test based on these findings, 2) develop the application of this testing methodology to a point of care SolCD44 pretreatment prognostic test, and 3) explore the value of SolCD44 as a dynamic indicator of risk of recurrence in oral/oropharyngeal cancer. At the end of this project, the OncAlert rapid POC kit will consist of a simple, inexpensive, point of care test for oral/oropharyngeal cancer risk. In addition, confirmation of the independent prognostic value of SolCD44 in oral/oropharyngeal in recurrence free survival will form the basis for application to expand SolCD44 as an approved prognostic test for oral/oropharyngeal cancer. Finally we will explore the potential for SolCD44 to provide a dynamic indication of disease status in these cancers.

鳞状细胞癌，包括口腔和口咽的癌，占所有癌的90％以上影响这些组织的癌症（1）。简单地提供通用的专家临床检查将无法满足需要改善口服/口咽癌的早期诊断。准确的开发和验证评估口服/口咽癌风险的测试有可能改善治疗结果，减少相关的发病率，并降低治疗成本。唾液冲洗可溶性CD44（Solcd44）和唾液冲洗总蛋白的结合警惕的生物科学表明，与常规的癌症相比，口服癌的检测更为准确此外，检测技术（5,30,31）此外，SOLCD44与预后不良有关在这些癌症中。该项目将1）继续开发独特，稳定，廉价，无创，易于使用，基于这些发现，口服/口咽癌特异性，快速护理（POC）风险评估测试； 2）将此测试方法的应用在护理点Solcd44预后测试中， 3）探索SOLCD44的价值，这是口服/口咽癌中复发风险的动态指标。在该项目结束时，Oncalert快速POC套件将包括一个简单，廉价的护理点测试口服/口咽癌风险。另外，确认独立的预后价值 solcd44在无复发生存中的口服/口咽中 SOLCD44作为口服/口咽癌的批准预后测试。最后，我们将探索潜力 SOLCD44提供了这些癌症中疾病状态的动态指示。